Molecular biology of cholesteatoma

Romanian Journal of Morphology and Embryology

Volumn 55, Issue 1, 2014, Pages 7-13

  Maniu, Alma ^a   Harabagiu, Oana ^a   Schrepler, Maria Perde ^b   Cǎtanǎ, Andreea ^a   Fǎnuţǎ, Bogdan ^c   Mogoantǎ, Carmen Aurelia ^c,d  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c EMERGENCY COUNTY HOSPITAL   (Romania)

^d UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Cholesteatoma; Gene expressions; Inflammatory mediators; Molecular biology; Proliferation markers

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; SIGNAL PEPTIDE;

CELL PROLIFERATION; CHOLESTEATOMA; ENZYMOLOGY; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

BIOLOGICAL MARKERS; CELL PROLIFERATION; CHOLESTEATOMA; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OXIDATIVE STRESS;

EID: 84898619527     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Louw L, Acquired cholesteatoma pathogenesis: stepwise explanations, J Laryngol Otol, 2010, 124(6):587-593.
2. Suchozebrska-Jesionek D, Szymański M, Kurzepa J, Gołabek W, Stryjecka-Zimmer M, Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma, J Otolaryngol Head Neck Surg, 2008, 37(5):628-632.
3. Derlacki EL, Clemis JD, Congenital cholesteatoma of the middle ear and mastoid, Ann Otol Rhinol Laryngol, 1965, 74(3):706-727.
4. Michaels L, An epidermoid formation in the developing middle ear: possible source of cholesteatoma, J Otolaryngol, 1986, 15(3):169-174.
5. Karmody CS, Byahatti SV, Blevins N, Valtonen H, Northrop C, The origin of congenital cholesteatoma, Am J Otol, 1998, 19(3):292-297.
6. Albera R, Canale A, Piumetto E, Lacilla M, Dagna F, Ossicular chain lesions in cholesteatoma, Acta Otorhinolaryngol Ital, 2012, 32(5):309-313.
7. Potsic WP, Samadi DS, Marsh RR, Wetmore RF, A staging system for congenital cholesteatoma, Arch Otolaryngol Head Neck Surg, 2002, 128(9):1009-1012.
8. Kim YH, Yoo JC, Lee JH, Oh SH, Chang SO, Koo JW, Kim CS, Stage progression of congenital cholesteatoma in children, Eur Arch Otorhinolaryngol, 2012, 269(3):833-837.
9. Persaud R, Hajioff D, Trinidade A, Khemani S, Bhattacharyya MN, Papadimitriou N, Kalan A, Bhattacharyya AK, Evidencebased review of aetiopathogenic theories of congenital and acquired cholesteatoma, J Laryngol Otol, 2007, 121(11): 1013-1019.
10. Sudhoff HH, Tos M, Pathogenesis of attic cholesteatoma: clinical and immunohistochemical support for combination of retraction theory and proliferation theory, Am J Otol, 2000, 21(6):786-792.
11. Michaels L, Biology of cholesteatoma, Otolaryngol Clin North Am, 1989, 22(5):869-881.
12. Lim DJE, Saunders WH, Acquired cholesteatoma: light and electron microscopic observations, Ann Otol Rhinol Laryngol, 1972, 81(1):1-11.
13. Juhn SK, Jung MK, Hoffman MD, Drew BR, Preciado DA, Sausen NJ, Jung TT, Kim BH, Park SY, Lin J, Ondrey FG, Mains DR, Huang T, The role of inflammatory mediators in the pathogenesis of otitis media and sequelae, Clin Exp Otorhino-laryngol, 2008, 1(3):117-138.
14. Louw L, Acquired cholesteatoma: summary of the cascade of molecular events, J Laryngol Otol, 2013, 127(6):542-549.
15. Kupper TS, The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses, J Invest Dermatol, 1990, 94(6 Suppl):146S-150S.
16. Albino AP, Reed JA, Bogdany JK, Sassoon J, Parisier SC, Increased number of mast cells in human middle ear cholesteatomas: implications for treatment, Am J Otol, 1998, 19(3):266-272.
17. Schilling V, Bujía J, Negri B, Schulz P, Kastenbauer E, Immunologically activated cells in aural cholesteatoma, Am J Otolaryngol, 1991, 12(5):249-253.
18. Albino AP, Kimmelman CP, Parisier SC, Cholesteatoma: a molecular and cellular puzzle, Am J Otol, 1998, 19(1):7-19.
19. Akimoto R, Pawankar R, Yagi T, Baba S, Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin- 1-alpha and lymphocyte functional antigen-1 in the inflammatory process, ORL J Otorhinolaryngol Relat Spec, 2000, 62(5):257-265.
20. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR, Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors, Nature, 1986, 322(6053):516-518.
21. Dayer JM, Beutler B, Cerami A, Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts, J Exp Med, 1985, 162(6):2163-2168.
22. Saklatvala J, Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage, Nature, 1986, 322(6079):547-549.
23. Shiwa M, Kojima H, Kamide Y, Moriyama H, Involvement of interleukin-1 in middle ear cholesteatoma, Am J Otolaryngol, 1995, 16(5):319-324.
24. Kim CS, Lee CH, Chung JW, Kim CD, Interleukin-1 alpha, interleukin-1 beta and interleukin-8 gene expression in human aural cholesteatomas, Acta Otolaryngol, 1996, 116(2):302-306.
25. Didierjean L, Salomon D, Mérot Y, Siegenthaler G, Shaw A, Dayer JM, Saurat JH, Localization and characterization of the interleukin 1 immunoreactive pool (IL-1 alpha and beta forms) in normal human epidermis, J Invest Dermatol, 1989, 92(6):809-816.
26. Miyasato M, Takeno S, Hirakawa K, Expression of RANKL and proliferation abilities of cultured human middle ear cholesteatoma epithelial cells, Hiroshima J Med Sci, 2013, 62(1):1-6.
27. Schönermark M, Mester B, Kempf HG, Bläser J, Tschesche H, Lenarz T, Expression of matrix-metalloproteinases and their inhibitors in human cholesteatomas, Acta Otolaryngol, 1996, 116(3):451-456.
28. Visse R, Nagase H, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry, Circ Res, 2003, 92(8):827-839.
29. Juhász A, Sziklai I, Rákosy Z, Ecsedi S, Adány R, Balázs M, Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas, Otol Neurotol, 2009, 30(4):559-565.
30. Laeeq S, Faust R, Modeling the cholesteatoma microenvironment: coculture of HaCaT keratinocytes with WS1 fibroblasts induces MMP-2 activation, invasive phenotype, and proteolysis of the extracellular matrix, Laryngoscope, 2007, 117(2):313-318.
31. Rezende CEB, do Souto RP, Rapoport PB, de Campos L, Generato MB, Cholesteatoma gene expression of matrix metalloproteinases and their inhibitors by RT-PCR, Braz J Otorhinolaryngol, 2012, 78(3):116-121.
32. Bujía J, Kim C, Holly A, Sudhoff H, Ostos P, Kastenbauer E, Epidermal growth factor receptor (EGF-R) in human middle ear cholesteatoma: an analysis of protein production and gene expression, Am J Otol, 1996, 17(2):203-206.
33. Olszewska E, Wagner M, Bernal-Sprekelsen M, Ebmeyer J, Dazert S, Hildmann H, Sudhoff H, Etiopathogenesis of cholesteatoma, Eur Arch Otorhinolaryngol, 2004, 261(1):6-24.
34. Ergün S, Zheng X, Carlsöö B, Expression of transforming growth factor-alpha and epidermal growth factor receptor in middle ear cholesteatoma, Am J Otol, 1996, 17(3):393-396.
35. Taysi S, Memisogullari R, Koc M, Yazici AT, Aslankurt M, Gumustekin K, Al B, Ozabacigil F, Yilmaz A, Tahsin Ozder H, Melatonin reduces oxidative stress in the rat lens due to radiation-induced oxidative injury, Int J Radiat Biol, 2008, 84(10):803-808.
36. Aktan B, Gundogdu C, Ucuncu H, Unal B, Sütbeyaz Y, Altas S, Anti-inflammatory effect of erythromycin on histamineinduced otitis media with effusion in guinea pigs, J Laryngol Otol, 2004, 118(2):97-101.
37. Okumus S, Taysi S, Orkmez M, Saricicek E, Demir E, Adli M, Al B, The effects of oral Ginkgo biloba supplementation on radiation-induced oxidative injury in the lens of rat, Pharmacogn Mag, 2011, 7(26):141-145.
38. Baysal E, Aksoy N, Kara F, Taysi S, Taşkin A, Bilinç H, Cevik C, Celenk F, Kanlikama M, Oxidative stress in chronic otitis media, Eur Arch Otorhinolaryngol, 2013, 270(4):1203-1208.
39. Chole RA, Sudhoff HH, Chapter 139: Chronic otitis media, mastoiditis, and petrositis. In: Flint PW, Haughey BH, Lund VJ, Niparko JK, Richardson MA, Robbins KT, Thomas JR (eds), Cummings otolaryngology: head & neck surgery, 5th edition, Mosby-Elsevier, Philadelphia, 2010, 1963-1977.
40. Bjarnsholt T, The role of bacterial biofilms in chronic infections, APMIS Suppl, 2013, 136:1-51.
41. Lampikoski H, Aarnisalo AA, Jero J, Kinnari TJ, Mastoid biofilm in chronic otitis media, Otol Neurotol, 2012, 33(5):785-788.
42. Rayner MG, Zhang Y, Gorry MC, Chen Y, Post JC, Ehrlich GD, Evidence of bacterial metabolic activity in culture-negative otitis media with effusion, JAMA, 1998, 279(4):296-299.
43. Preciado D, Caicedo E, Jhanjee R, Silver R, Harris G, Juhn SK, Choo DI, Ondrey F, Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF-kappa B, and cyclin D1 is inhibited by indomethacin, J Immunol, 2005, 174(5):2964-2973.
44. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr, NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1, Mol Cell Biol, 1999, 19(8):5785-5799.
45. Hamajima Y, Komori M, Preciado DA, Choo DI, Moribe K, Murakami S, Ondrey FG, Lin J, The role of inhibitor of DNA-binding (Id1) in hyperproliferation of keratinocytes: the pathological basis for middle ear cholesteatoma from chronic otitis media, Cell Prolif, 2010, 43(5):457-463.
46. Kwon KH, Kim SJ, Kim HJ, Jung HH, Analysis of gene expression profiles in cholesteatoma using oligonucleotide microarray, Acta Otolaryngol, 2006, 126(7):691-697.
47. Caliman e Gurgel JD, Pereira SB, Alves AL, Ribeiro FQ, Hyperproliferation markers in ear canal epidermis, Braz J Otorhinolaryngol, 2010, 76(5):667-671.
48. Vennix PP, Kuijpers W, Peters TA, Tonnaer EL, Ramaekers FC, Keratinocyte differentiation in acquired cholesteatoma and perforated tympanic membranes, Arch Otolaryngol Head Neck Surg, 1996, 122(8):825-832.
49. Kim HJ, Tinling SP, Chole RA, Expression patterns of cytokeratins in retraction pocket cholesteatomas, Laryngoscope, 2001, 111(6):1032-1036.
50. Sharma SC, Sikka K, Thakar A, Dattagupta S, Epithelial proliferation in cholesteatoma, Otolaryngol Head Neck Surg, 2012, 147(2 Suppl):P208.
51. Woo HJ, Park JC, Bae CH, Song SY, Lee HM, Kim YD, Up-regulation of neutrophil gelatinase-associated lipocalin in cholesteatoma, Acta Otolaryngol, 2009, 129(6):624-629.
52. Bassiouny M, Badour N, Omran A, Osama H, Histopathological and immunohistochemical characteristics of acquired cholesteatoma in children and adults, Egypt J Ear Nose Throat Allied Sci, 2012, 13(1):7-12.
53. Shinoda H, Huang CC, Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death, Laryngoscope, 1995, 105(11):1232-1237.
54. Choufani G, Ghanooni R, Decaestecker C, Delbrouck K, Simon P, Schüring MP, Zick Y, Hassid S, Gabius HJ, Kiss R, Detection of macrophage migration inhibitory factor (MIF) in human cholesteatomas and functional implications of correlations to recurrence status and to expression of matrix metalloproteinases- 3/9, retinoic acid receptor-beta, and anti-apoptotic galectin-3, Laryngoscope, 2001, 111(9):1656-1662.
55. Huisman M, de Heer E, Ten Dijke P, Grote JJ, Transforming growth factor beta and wound healing in human cholesteatoma, Laryngoscope, 2008, 118(1):94-98.
56. Shunyu NB, Gupta SD, Thakar A, Sharma SC, Histological and immunohistochemical study of pars tensa reaction pocket, Otolaryngol Head Neck Surg, 2011, 145(4):628-634.
57. Wells MD, Michaels L, Mode of growth of acquired cholesteatoma, J Laryngol Otol, 1991, 105(4):261-267.
58. Blons H, Laccourreye O, Houllier AM, Carnot F, Brasnu D, Beaune P, Zucman-Rossi J, Laurent-Puig P, Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma, Oncogene, 2002, 21(32):5016-5023.
59. Hajra KM, Fearon ER, Cadherin and catenin alterations in human cancer, Genes Chromosomes Cancer, 2002, 34(3): 255-268.
60. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S, Yuen ST, Leung SY, Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma, Oncogene, 2003, 22(44):6946-6953.
61. Xu J, Wu S, Shi X, Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma, J Orthop Res, 2010, 28(12):1621-1625.
62. Klenke C, Janowski S, Borck D, Widera D, Ebmeyer J, Kalinowski J, Leichtle A, Hofestädt R, Upile T, Kaltschmidt C, Kaltschmidt B, Sudhoff H, Identification of novel cholesteatomarelated gene expression signatures using full-genome microarrays, PLoS One, 2012, 7(12):e52718.